TRPM2 and neuroblastoma: Treatment of TRPM2-knockout neuroblastoma cells with doxorubicin decreased cell viability, RNAs encoding for transcription factors, E2F1/2 and FOXM1, and cell cycle regulators, including CDK1, Cyclin B1, CKS1, and PLK (229).